EUR 0.06
(-4.72%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 6.49 Million EUR | 1169.52% |
2022 | 511.39 Thousand EUR | 19735.51% |
2021 | 2578.20 EUR | 1886.29% |
2020 | 129.80 EUR | -29.03% |
2019 | 182.90 EUR | -1.77% |
2018 | 186.20 EUR | -13.4% |
2017 | 215.00 EUR | 33.13% |
2016 | 161.50 EUR | -8.34% |
2015 | 176.20 EUR | -99.9% |
2014 | 169.4 Thousand EUR | -3.86% |
2013 | 176.2 Thousand EUR | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 FY | 6.49 Million EUR | 1169.52% |
2023 Q4 | 6.49 Million EUR | 0.0% |
2023 Q2 | 6.34 Million EUR | 0.0% |
2022 FY | 511.39 Thousand EUR | 19735.51% |
2022 Q4 | 511.39 Thousand EUR | 0.0% |
2022 Q2 | 3.4 Million EUR | 0.0% |
2021 Q2 | 96.5 Thousand EUR | 0.0% |
2021 Q4 | 2578.20 EUR | 0.0% |
2021 FY | 2578.20 EUR | 1886.29% |
2020 FY | 129.80 EUR | -29.03% |
2020 Q4 | 129.80 EUR | 0.0% |
2020 Q2 | 170.70 EUR | 0.0% |
2019 FY | 182.90 EUR | -1.77% |
2019 Q2 | 181.00 EUR | 0.0% |
2019 Q4 | 182.90 EUR | 0.0% |
2018 Q2 | 184.00 EUR | 0.0% |
2018 FY | 186.20 EUR | -13.4% |
2018 Q4 | 186.20 EUR | 0.0% |
2017 Q2 | 215.30 EUR | 0.0% |
2017 FY | 215.00 EUR | 33.13% |
2017 Q4 | 215.00 EUR | 0.0% |
2016 FY | 161.50 EUR | -8.34% |
2016 Q4 | 161.50 EUR | 0.0% |
2016 Q2 | 172.50 EUR | 0.0% |
2015 Q4 | 176.20 EUR | 0.0% |
2015 FY | 176.20 EUR | -99.9% |
2015 Q2 | 172.7 Thousand EUR | 0.0% |
2014 FY | 169.4 Thousand EUR | -3.86% |
2014 Q4 | 169.4 Thousand EUR | 0.0% |
2013 FY | 176.2 Thousand EUR | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
ABIONYX Pharma SA | 1.1 Million EUR | -489.673% |
ABIVAX Société Anonyme | 44.69 Million EUR | 85.475% |
Adocia SA | 4.54 Million EUR | -43.002% |
Aelis Farma SA | 2.04 Million EUR | -217.007% |
Biophytis S.A. | 3.11 Million EUR | -108.689% |
Advicenne S.A. | 15.89 Million EUR | 59.158% |
genOway Société anonyme | 5.51 Million EUR | -17.629% |
IntegraGen SA | 642.28 Thousand EUR | -910.821% |
Medesis Pharma S.A. | 1.2 Million EUR | -441.025% |
Neovacs S.A. | 650 Thousand EUR | -898.815% |
NFL Biosciences SA | 39.2 Thousand EUR | -16460.722% |
Plant Advanced Technologies SA | 4.35 Million EUR | -49.025% |
Quantum Genomics Société Anonyme | 1.96 Million EUR | -231.184% |
Sensorion SA | 1.24 Million EUR | -423.188% |
Theranexus Société Anonyme | 2.46 Million EUR | -163.838% |
TME Pharma N.V. | - EUR | -Infinity% |
Valbiotis SA | 3.89 Million EUR | -66.555% |
TheraVet SA | 1 Million EUR | -548.841% |
Valerio Therapeutics Société anonyme | 6.9 Million EUR | 5.99% |
DBV Technologies S.A. | 4.52 Million USD | -43.445% |
Genfit S.A. | 62.25 Million EUR | 89.571% |
Innate Pharma S.A. | 30.6 Million EUR | 78.788% |
Inventiva S.A. | 25.61 Million EUR | 74.655% |
MaaT Pharma SA | 5.42 Million EUR | -19.674% |
MedinCell S.A. | 52.8 Million EUR | 87.704% |
Nanobiotix S.A. | 41.66 Million EUR | 84.416% |
OSE Immunotherapeutics SA | 35.5 Million EUR | 81.716% |
Poxel S.A. | 40.14 Million EUR | 83.827% |
GenSight Biologics S.A. | 1.04 Million EUR | -519.494% |
Transgene SA | 17 Thousand EUR | -38090.0% |
Valneva SE | 132.76 Million EUR | 95.11% |